Lorena Jara‐Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorena Jara‐Fernández has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Conrado Manuel Fernández Rodriguez
Service of Gastroenterology University Hospital Fundación Alcorcón Alcorcón Madrid Spain
2 shared publications - Henar Calvo‐Sánchez
Service of Gastroenterology University Hospital of Guadalajara Guadalajara Spain
2 shared publications - Juan Ramón Larrubia
Service of Gastroenterology University Hospital of Guadalajara Guadalajara Spain
2 shared publications - Irene Villarino
Service of Gastroenterology University Hospital of Guadalajara Guadalajara Spain
1 shared publication - Joaquín Miquel
Service of Gastroenterology University Hospital of Guadalajara Guadalajara Spain
1 shared publication - José Gómez
Department of Biology and Geology, Physics and Inorganic Chemistry, ESCET, Rey Juan Carlos University, E28933 Móstoles, Madrid, Spain
1 shared publication
Latest Publications
- 5 November 2026
- Published by Wiley in Liver International
- Vol. 46 (12) , e70977
Response to He: Exposure Timing and Causal Interpretation in Competing‐Risk Analyses of Metformin and Hepatocellular Carcinoma
- 5 November 2026
- Published by Wiley in Liver International
- Vol. 46 (12) , e70977
Response to He: Exposure Timing and Causal Interpretation in Competing‐Risk Analyses of Metformin and Hepatocellular Carcinoma
- Open Access
- 24 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70798
Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study
Background: Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR. Methods: We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment. Results: During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001). Conclusion: After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.
- 24 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70798
Open AccessCumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study
Background: Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR. Methods: We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment. Results: During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001). Conclusion: After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.